A Disproportionality Analysis on Benzoyl Peroxide and Its Risk of Malignancy Using the FDA Adverse Event Reporting System

J Invest Dermatol. 2025 Sep;145(9):2351-2354.e1. doi: 10.1016/j.jid.2025.02.139. Epub 2025 Mar 7.

Authors

Kerry Yang¹, Sonia Czyz¹, Rayyan Zuberi¹, Jason Kreutz¹, Christopher G Bunick², Fatemeh Jafarian³

Affiliations

¹ Department of Medicine, University of Calgary, Calgary, Canada.
² Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Program in Translational Biomedicine, Yale School of Medicine, New Haven, Connecticut, USA.
³ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Canada. Electronic address: Fatemeh.jafarian@ucalgary.ca.

PMID: 40058570
DOI: 10.1016/j.jid.2025.02.139

No abstract available

Keywords: Acne; Adapalene; Cancer; Neoplasm; Pharmacovigilance.